TIDMVSN
Verseon Corporation
12 June 2017
Press release June 12, 2017
Verseon Corporation
("Verseon" or the "Company")
Verseon to present preclinical data on diabetic macular edema
program and update on anticoagulation program at BIO 2017
Fremont, Calif.-Verseon, a technology-based pharmaceutical
company employing a computer-driven platform to develop a diverse
drug pipeline, today announces that it will present its most
advanced drug programs at the 2017 BIO International Conference,
one of the world's largest biotechnology events, held June 19-22,
2017 in San Diego.
Dr. David Kita, Vice President of R&D at Verseon, will
present preclinical results on the Company's plasma kallikrein
inhibitors for the treatment of diabetic macular edema (DME), a
major cause of blindness worldwide that affects people with
diabetes. The presentation will include pharmacokinetic data
indicating that Verseon's drug candidates can be administered as
eye drops. Moreover, some of Verseon's kallikrein inhibitors are
suitable for oral dosing.
A second presentation will provide an update on Verseon's
anticoagulation program. The Company's direct thrombin inhibitors
have demonstrated efficacy comparable to existing anticoagulants in
preclinical testing, but lower bleeding risk. In addition to
results on Verseon's first development candidate, which shows
significantly lower renal clearance than the current
anticoagulants, Dr. Kita will also present new preclinical data on
another promising lead candidate with a distinct chemotype.
"Our computer-driven approach to drug discovery has allowed us
to develop multiple promising candidates across our pipeline," said
Dr. Kita. "We are especially excited to share preclinical results
on our DME candidates, which can potentially have a positive impact
on millions of patients worldwide."
Details of the presentations are as follows:
Anticoagulation program
Date and Time: Monday, June 19, 2017; 4:45 p.m.
Location: Company Presentation Theater 2
Abstract: https:/mybio.org/event/member/381843
Diabetic macular edema program
Date and Time: Thursday, June 22, 2017; 11:45 a.m.
Location: Company Presentation Theater 2
Abstract: https://mybio.org/event/member/378540
About Verseon's diabetic macular edema program
Verseon has developed a new class of potent, selective compounds
for the treatment of diabetic macular edema. The Company's plasma
kallikrein inhibitors target a validated pathway addressing an
underlying cause of the disease. In preclinical testing, Verseon's
inhibitors show favorable biochemical properties permitting either
oral or topical (eye drop) administration.
About Verseon's anticoagulation program
Verseon's potent, highly selective, oral direct thrombin
inhibitors act through reversible covalent inhibition, a unique
mode of action. Preclinical studies show that Verseon's inhibitors
act as effective anticoagulants in multiple efficacy studies, but
do not disrupt platelet function. This unique feature could explain
their observed low bleeding risk. One of Verseon's lead candidates
furthermore shows very low renal clearance, a highly desirable
property for patients with impaired renal function.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
About BIO International Convention 2017
The BIO International Convention is one of the world's largest
gatherings of the biotechnology industry, with industry-leading
investor and partnering meetings held around the world. With
16,000+ attendees, 1,800+ exhibitors, and 500+ companies, it
represents an ideal platform for biopharma's top people and most
innovative technologies. BIO 2017, organized by the Biotechnology
Innovation Organization (BIO), will be held San Diego, June 19-22,
2017.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSAFWUFWSESM
(END) Dow Jones Newswires
June 12, 2017 02:01 ET (06:01 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024